12.82
price down icon0.70%   -0.09
after-market Dopo l'orario di chiusura: 12.82
loading
Precedente Chiudi:
$12.91
Aprire:
$12.91
Volume 24 ore:
378.42K
Relative Volume:
0.90
Capitalizzazione di mercato:
$298.32M
Reddito:
$157.75M
Utile/perdita netta:
$-29.73M
Rapporto P/E:
-11.05
EPS:
-1.16
Flusso di cassa netto:
$-21.00M
1 W Prestazione:
+16.55%
1M Prestazione:
+10.71%
6M Prestazione:
-34.49%
1 anno Prestazione:
-51.71%
Intervallo 1D:
Value
$12.25
$13.20
Intervallo di 1 settimana:
Value
$11.13
$13.66
Portata 52W:
Value
$8.04
$45.00

Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile

Name
Nome
Arcturus Therapeutics Holdings Inc
Name
Telefono
(858) 900-2660
Name
Indirizzo
10628 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Name
Dipendente
176
Name
Cinguettio
@ArcturusRx
Name
Prossima data di guadagno
2024-11-07
Name
Ultimi documenti SEC
Name
ARCT's Discussions on Twitter

Confronta ARCT con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ARCT
Arcturus Therapeutics Holdings Inc
12.82 298.32M 157.75M -29.73M -21.00M -1.16
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
496.49 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.86 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
620.97 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
254.85 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
249.46 24.70B 3.81B -644.79M -669.77M -6.24

Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-01-28 Iniziato BTIG Research Buy
2024-08-12 Iniziato Leerink Partners Outperform
2023-12-13 Iniziato Canaccord Genuity Buy
2023-07-24 Iniziato William Blair Outperform
2023-05-11 Aggiornamento H.C. Wainwright Neutral → Buy
2022-11-14 Ripresa Wells Fargo Overweight
2022-11-10 Downgrade Robert W. Baird Neutral → Underperform
2022-11-03 Aggiornamento Citigroup Neutral → Buy
2022-11-02 Aggiornamento Barclays Underweight → Equal Weight
2022-08-10 Downgrade Raymond James Mkt Perform → Underperform
2022-07-19 Ripresa Cantor Fitzgerald Overweight
2022-05-11 Aggiornamento Robert W. Baird Underperform → Neutral
2022-04-21 Downgrade Citigroup Buy → Neutral
2022-01-31 Aggiornamento Raymond James Underperform → Mkt Perform
2021-08-12 Downgrade Raymond James Mkt Perform → Underperform
2021-08-11 Downgrade Goldman Neutral → Sell
2021-08-10 Downgrade Robert W. Baird Neutral → Underperform
2021-07-02 Iniziato Cantor Fitzgerald Overweight
2021-06-25 Ripresa Goldman Neutral
2021-06-21 Downgrade Barclays Equal Weight → Underweight
2021-06-04 Ripresa Robert W. Baird Neutral
2021-02-17 Downgrade B. Riley Securities Neutral → Sell
2021-01-19 Downgrade B. Riley Securities Buy → Neutral
2021-01-15 Downgrade B. Riley Securities Buy → Neutral
2021-01-07 Iniziato Wells Fargo Overweight
2020-12-29 Downgrade Barclays Overweight → Equal Weight
2020-12-29 Downgrade H.C. Wainwright Buy → Neutral
2020-12-29 Downgrade Raymond James Outperform → Mkt Perform
2020-12-29 Downgrade Robert W. Baird Outperform → Neutral
2020-12-23 Downgrade ROTH Capital Buy → Sell
2020-12-08 Reiterato B. Riley Securities Buy
2020-12-07 Reiterato B. Riley Securities Buy
2020-10-26 Iniziato Barclays Overweight
2020-10-06 Iniziato Citigroup Buy
2020-08-26 Iniziato Piper Sandler Overweight
2020-07-30 Ripresa ROTH Capital Buy
2020-07-16 Iniziato Raymond James Outperform
2020-07-13 Iniziato B. Riley FBR Buy
2020-06-09 Downgrade WBB Securities Buy → Hold
2020-02-11 Iniziato Robert W. Baird Outperform
2020-02-07 Iniziato Guggenheim Buy
2020-02-06 Iniziato Guggenheim Buy
2019-04-05 Iniziato H.C. Wainwright Buy
2018-09-20 Aggiornamento WBB Securities Buy → Strong Buy
2018-01-22 Iniziato Chardan Capital Markets Buy
Mostra tutto

Arcturus Therapeutics Holdings Inc Borsa (ARCT) Ultime notizie

pulisher
Apr 24, 2025

Geode Capital Management LLC Has $9.42 Million Stock Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World

Apr 24, 2025
pulisher
Apr 23, 2025

Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress - ADVFN

Apr 23, 2025
pulisher
Apr 22, 2025

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025 - Business Wire

Apr 22, 2025
pulisher
Apr 22, 2025

Long Term Trading Analysis for (ARCT) - news.stocktradersdaily.com

Apr 22, 2025
pulisher
Apr 21, 2025

JPMorgan Chase & Co. Has $4.01 Million Holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World

Apr 21, 2025
pulisher
Apr 20, 2025

Research Analysts Set Expectations for ARCT Q1 Earnings - American Banking and Market News

Apr 20, 2025
pulisher
Apr 19, 2025

Q1 Earnings Estimate for ARCT Issued By Leerink Partnrs - Defense World

Apr 19, 2025
pulisher
Apr 18, 2025

European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine (PR Newswire) - Aktiellt

Apr 18, 2025
pulisher
Apr 15, 2025

Vanguard Group Inc. Grows Holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World

Apr 15, 2025
pulisher
Apr 14, 2025

Can The Upcoming Catalysts Breathe New Life Into Arcturus Therapeutics? - RTTNews

Apr 14, 2025
pulisher
Apr 13, 2025

Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate - MSN

Apr 13, 2025
pulisher
Apr 12, 2025

KLP Kapitalforvaltning AS Acquires New Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World

Apr 12, 2025
pulisher
Apr 12, 2025

HC Wainwright Reiterates Buy Rating for Arcturus Therapeutics (NASDAQ:ARCT) - Defense World

Apr 12, 2025
pulisher
Apr 11, 2025

High Growth Tech Stocks To Watch In The US April 2025 - simplywall.st

Apr 11, 2025
pulisher
Apr 11, 2025

Arcturus Therapeutics (ARCT) Gains FDA Fast Track for Influenza Vaccine - GuruFocus

Apr 11, 2025
pulisher
Apr 11, 2025

Arcturus Therapeutics (ARCT) Receives Fast Track Status for Infl - GuruFocus

Apr 11, 2025
pulisher
Apr 11, 2025

Arcturus Therapeutics Receives U.S. FDA Fast Track Designation f - GuruFocus

Apr 11, 2025
pulisher
Apr 11, 2025

Guggenheim Lowers Price Target for Arcturus Therapeutics (ARCT) Amid Risk Adjustments | ARCT Stock News - GuruFocus

Apr 11, 2025
pulisher
Apr 10, 2025

Arcturus wins FDA fast track status for influenza vaccine - MSN

Apr 10, 2025
pulisher
Apr 10, 2025

Arcturus wins FDA fast track status for flu shot (ARCT:NASDAQ) - Seeking Alpha

Apr 10, 2025
pulisher
Apr 10, 2025

Arcturus Therapeutics Says FDA Granted Fast Track Designation to Potential H5N1 Vaccine - marketscreener.com

Apr 10, 2025
pulisher
Apr 10, 2025

Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1 - Business Wire

Apr 10, 2025
pulisher
Apr 10, 2025

Breakthrough: FDA Fast-Tracks Revolutionary mRNA Vaccine Against Deadly H5N1 Pandemic Flu - Stock Titan

Apr 10, 2025
pulisher
Apr 09, 2025

Commonwealth Equity Services LLC Reduces Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World

Apr 09, 2025
pulisher
Apr 07, 2025

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $59.20 Consensus Price Target from Brokerages - Defense World

Apr 07, 2025
pulisher
Apr 06, 2025

(ARCT) Investment Report - news.stocktradersdaily.com

Apr 06, 2025
pulisher
Mar 26, 2025

(ARCT) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Mar 26, 2025
pulisher
Mar 24, 2025

Bank of New York Mellon Corp Sells 22,024 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World

Mar 24, 2025
pulisher
Mar 20, 2025

Is Arcturus Therapeutics (ARCT) a Worst High-Risk High-Reward Growth Stock to Buy? - Insider Monkey

Mar 20, 2025
pulisher
Mar 20, 2025

Benign Growth For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Underpins Stock's 26% Plummet - simplywall.st

Mar 20, 2025
pulisher
Mar 18, 2025

Arcturus up 9% as phase 2 dosing begins for mRNA asset for cystic fibrosis - MSN

Mar 18, 2025
pulisher
Mar 17, 2025

William Blair Issues Pessimistic Outlook for ARCT Earnings - Defense World

Mar 17, 2025
pulisher
Mar 16, 2025

(ARCT) Proactive Strategies - news.stocktradersdaily.com

Mar 16, 2025
pulisher
Mar 13, 2025

Arcturus Therapeutics Holdings Inc to Host Earnings Call - ACCESS Newswire

Mar 13, 2025
pulisher
Mar 13, 2025

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $61.40 Average PT from Analysts - Defense World

Mar 13, 2025
pulisher
Mar 12, 2025

Arcturus Therapeutics at Leerink’s Conference: mRNA Innovations and Strategic Plans - Investing.com UK

Mar 12, 2025
pulisher
Mar 12, 2025

Despite Revenue Setback, Arcturus Therapeutics (ARCT) Vaccine Breakthroughs Fuel Optimism - markets.businessinsider.com

Mar 12, 2025
pulisher
Mar 11, 2025

Arcturus Therapeutics (NASDAQ:ARCT) Given New $68.00 Price Target at Canaccord Genuity Group - Defense World

Mar 11, 2025
pulisher
Mar 09, 2025

Analysts Have Lowered Expectations For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) After Its Latest Results - Simply Wall St

Mar 09, 2025
pulisher
Mar 09, 2025

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Are Cutting Their Estimates: Here's What You Need To Know - Yahoo

Mar 09, 2025
pulisher
Mar 09, 2025

HC Wainwright Lowers Arcturus Therapeutics (NASDAQ:ARCT) Price Target to $60.00 - Defense World

Mar 09, 2025
pulisher
Mar 09, 2025

Arcturus Therapeutics (NASDAQ:ARCT) Earns Overweight Rating from Cantor Fitzgerald - Defense World

Mar 09, 2025
pulisher
Mar 08, 2025

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 08, 2025
pulisher
Mar 07, 2025

Arcturus Therapeutics stock hits 52-week low at $14.3 By Investing.com - Investing.com Australia

Mar 07, 2025
pulisher
Mar 07, 2025

Beyond The Numbers: 8 Analysts Discuss Arcturus Therapeutics Stock - Benzinga

Mar 07, 2025
pulisher
Mar 07, 2025

Arcturus Therapeutics stock hits 52-week low at $14.3 - Investing.com India

Mar 07, 2025
pulisher
Mar 07, 2025

Earnings call transcript: Arcturus Therapeutics Q4 2024 misses estimates By Investing.com - Investing.com South Africa

Mar 07, 2025
pulisher
Mar 07, 2025

Arcturus Therapeutics Reports Q4 2024 Earnings: EPS of ($1.11) M - GuruFocus.com

Mar 07, 2025
pulisher
Mar 07, 2025

Arcturus Therapeutics Holdings Inc (ARCT) Q4 2024 Earnings Call Highlights: Navigating ... - Yahoo Finance

Mar 07, 2025
pulisher
Mar 07, 2025

Arcturus Therapeutics Holdings Inc (ARCT) Q4 2024 Earnings Call - GuruFocus.com

Mar 07, 2025
pulisher
Mar 07, 2025

Arcturus Therapeutics Holdings Inc (ARCT) Q4 2024 Earnings Call Highlights: Navigating ... By GuruFocus - Investing.com Canada

Mar 07, 2025

Arcturus Therapeutics Holdings Inc Azioni (ARCT) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.63
price up icon 0.19%
$69.86
price up icon 0.24%
$32.54
price up icon 1.06%
$24.11
price up icon 2.75%
$104.00
price up icon 1.94%
biotechnology ONC
$249.46
price up icon 1.86%
Capitalizzazione:     |  Volume (24 ore):